Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium to prevent postoperative ARDS in perioperative intra-abdominal infection
ChiCTR2600125882Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Intra-abdominal infection (IAI) and acute respiratory distress syndrome (ARDS) comparing sivelestat sodium with Control: placebo (2 arms). Primary endpoints: Proportion completing ≥144 hours continuous infusion, Treatment-related discontinuation rate and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
sivelestat
03
Conditions
Intra-abdominal infection (IAI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2600125882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125882.